Preview of preclinical poster showing a next-generation oral small-molecule GLP-1 agonist's comparative efficacy and pharmacology in primate and mouse models.
Key Takeaways
- AMB-702 produced 12.6% placebo-adjusted mean weight loss after seven days in lean NHPs
- AMB-702 outperformed orforglipron, which showed 5.4% placebo-adjusted weight loss at identical dosing
- AMB-702 improved glycemic control and insulin secretion in a humanized GLP-1 receptor mouse model